Monaldi Archives for Chest Disease

Monaldi Archives for Chest Disease 2026; 96:3531
doi: 10.4081/monaldi.2025.3531

©Copyright: the Author(s), 2025
Licensee PAGEPress, Italy

Coexistence of upper airway obstruction on spirometry with flow volume loop in patients with chronic obstructive pulmonary disease

Dipika Koli, Ketaki Utpat, Unnati Desai, Nandakishore Arun

Department of Pulmonary Medicine, Bai Yamunabai Laxman Nair Hospital, Mumbai, Maharashtra, India

Abstract

Chronic obstructive pulmonary disease (COPD) can arise from smoking and non-smoking causes. Spirometry with flow–volume loop (FVL) analysis is a simple and essential test not only for diagnosing COPD but also for detecting upper airway obstruction (UAO). Identifying the coexistence of UAO in COPD has important clinical implications. The present study was an independent analysis of spirometry data from COPD patients (ECARP/2022/124) over 2 years at a tertiary care center. Various spirometry parameters and FVL patterns were assessed, including visual loop flattening, forced expiratory flow at 50% of vital capacity, forced inspiratory flow at 50% of vital capacity ratio (FEF_{50}/FIF_{50}), FIF_{50}, and Empey's index. Patients meeting ≥3 of 4 standard UAO criteria were classified as having UAO.

A total of 193 COPD patients were included (mean age 56.3 years). Visual loop flattening was observed in 27% (7% inspiratory, 20% expiratory). The FEF_{50}/FIF_{50} ratio was >1 in 17% and <0.3 in 44%, suggesting variable intrathoracic obstruction as the most common type of UAO. FIF_{50} <100 L/min was noted in 27.3%. Overall, 7.21% of patients met ≥3 of 4 diagnostic criteria for UAO.

Thus, a significant subset of COPD patients demonstrated features of coexisting UAO. Routine spirometry with FVL analysis provides a valuable, noninvasive tool to identify this overlap, which may influence diagnosis, management, and patient outcomes.

Key words: UAO, COPD, spirometry, flow volume loop, Empey's index, FEF_{50}/FIF_{50} ratio, FIF_{50}.

Correspondence to: Unnati Desai, Department of Pulmonary Medicine, Bai Yamunabai Laxman Nair Hospital, Mumbai, Maharashtra, India.
Tel.: 9769776985. E-mail: unnati_desai82@yahoo.co.in

Introduction

Chronic airway disease, which includes conditions like chronic obstructive pulmonary disease (COPD), bronchial asthma, bronchiectasis, and obliterative bronchiolitis, is a major contributor to respiratory-related morbidity and mortality [1]. COPD is a common but underrecognized condition and the only chronic disease with a steady rise in prevalence over the past 50 years. It now stands as the third leading cause of death worldwide, affecting over 400 million people [2]. The 2023 Global Initiative for Chronic Obstructive Lung Disease update redefined COPD and introduced a new taxonomy based on etiotypes: genetically determined (COPD-G), abnormal lung development (COPD-D), smoking-related (COPD-C), infection-related (COPD-I), pollution/environmental exposure (COPD-P), and unknown cause (COPD-U) [3]. A key feature of COPD is poorly reversible airway obstruction, mainly due to pathological changes in small airways (<2 mm). Their loss and narrowing increase the peripheral resistance and cause dynamic airway collapse during expiration, leading to airflow limitation [4]. The upper and lower airways form a continuous, integrated unit with similar responses to noxious stimuli [5]. The upper airway (UA) extends from the mouth up to the cricothyroid cartilage in the respiratory tract [6]. Upper airway obstructions (UAO) can be defined as a decrease in the diameter of the larynx, extra-thoracic or intrathoracic trachea, and main bronchi, presenting acutely or chronically based on the underlying etiology and type of obstruction. It is classified as variable UAO if obstruction changes with respiration, or fixed UAO if the site of obstruction remains constant. Variable UAO is further subdivided into variable extra-thoracic UAO (VET UAO) and variable intrathoracic UAO (VIT UAO) [7]. Spirometry with flow-volume loop (FVL) is a valuable, non-invasive tool for detecting UAO, often revealing early morphological changes before standard spirometry [7]. COPD dynamically involves small and large airways; hence, UAO may coexist. When both are present, it becomes difficult to determine each condition's contribution to respiratory impairment using only clinical evaluation, imaging, or standard pulmonary function tests alone [8]. This study focuses on utilizing spirometry to identify the coexistence of UAO in COPD and assess its impact on lung function. While laryngoscopy and bronchoscopy are the diagnostic gold standard, FVL offers a practical screening alternative. This study aims to assess the presence and features of UAO in COPD patients using FVL, highlighting the importance of early detection to improve outcomes and reduce healthcare burden.

Materials and Methods

This independent subset analysis focused on spirometry assessment of COPD databases collected in the Department of Pulmonary Medicine at a tertiary care hospital over a period of 18

months, following approval by the Institutional Ethics Committee (ECARP ref no-ECARP/2022/124). The study aimed to investigate the coexistence of UAO and types of UAO (*e.g.*, variable intrathoracic or extra-thoracic obstruction) in COPD patients using spirometry and FVL analysis. Informed consent was obtained from all participants. The study included all adult cases of COPD with clinical and radiological correlation and where a spirometry report was available, or the patient was able to perform a spirometry test.

Patients below 18 years, diagnosed cases of asthma, incomplete clinical data or diagnostic workups, or those not willing to participate were excluded from the study.

The spirometry was conducted using a Med Graphics Profiler DX Pulmonary Diagnostic System spirometer (Medical Graphics Corporation, Minnesota, USA), equipped with a dry pneumotachograph that met American Thoracic Society (ATS) spirometry guidelines [9]. The procedure involved inhaling to total lung capacity (TLC), followed by a forceful exhalation to residual volume (RV), and then rapid inhalation back to TLC, with a maximum of eight efforts allowed to comply with ATS standards. If a test was invalid or exceeded the limit, it was abandoned, and a new appointment was scheduled. The spirometer generated a FVL by plotting flow on the y-axis and volume on the x-axis, with a normal FVL showing a slight cove near RV due to compressive forces during exhalation and negative pressures during inhalation. The FVLs were analyzed qualitatively for signs of UAO, such as flattening of the inspiratory or expiratory loop or box-shaped loops. These findings were reviewed by a senior pulmonology resident and confirmed by a senior professor. Additionally, two quantitative indices were used to assess UAO: Empey's Index ([FEV1 (forced expiratory volume in 1 second)/PEF (peak expiratory flow) ratio >10 mL/L/min] and forced inspiratory flow at 50% of vital capacity (FIF_{50}≤100 L/min). The forced expiratory flow at 50% of vital capacity (FEF_{50})/FIF_{50} ratio was also calculated to distinguish between VET UAO and VIT UAO: FEF_{50}/FIF_{50}>1 for VET UAO and FEF_{50}/FIF_{50}<0.3 for VIT UAO. In fixed UAO, the FEF_{50}/FIF_{50} is 1. Continuous variables were reported as means with standard deviations and percentiles, while categorical variables were presented as frequencies and percentages.

The proportion of patients with UAO was determined, and statistical analysis was performed to evaluate the coexistence of UAO in COPD patients and the predictive value of FVL criteria.

Results

The study included 193 patients diagnosed with COPD, with a mean age of 56.3 years (±12.94), with 126 males and 67 females. Based on the etiotypes of COPD, out of 193 patients, 113 patients (58.5%) were diagnosed with COPD-I and 80 patients (41.45%) with COPD-C. All patients had breathlessness and cough. None had stridor, stertor, or hoarseness of voice. Mean FEV1 was 1.25 L (49.8%), and mean forced vital capacity was 1.93 L (61.72). On visual assessment of FVL, 141 patients (73%) had neither inspiratory nor expiratory loop flattening. FVL was abnormal in 27% of patients. Expiratory loop flattening, indicative of intrathoracic UAO, was observed in 39 patients (20%), including 9.3% of COPD-C and 10.8% of COPD-I patients. Inspiratory loop flattening, suggesting variable extra-thoracic UAO, was seen in 13 patients (7%), comprising 2% of COPD-C and 5% of COPD-I patients.

FIF_{50} was less than 100 L/min in 53 patients (27.3% of the total), including 14 patients (7.25%) with COPD-C and 39 patients (20.2%) with COPD-I. None of the patients had Empey's Index, *i.e.*, ratio of FEV1 to PEF >10 mL/L/min. The FEF_{50}/FIF_{50} ratio was greater than 1 in 33 patients (17%), including 6 patients with COPD-C (3.1%) and 27 with COPD-I (13.9%), indicating variable extra-thoracic obstruction. The FEF_{50}/FIF_{50} ratio was less than 0.3 in 44% of patients, including 23.8% of those with COPD-C and 20.2% with COPD-I, indicating that variable intrathoracic obstruction was the most prevalent type of UAO. Out of a total of 193 patients, 7.21% fulfilled at least 3 out of the following 4 criteria: i) visual loop showing inspiratory or expiratory loop flattening; ii) FEF_{50}/FIF_{50}<0.3 or FEF_{50}/FIF_{50}>1; iii) FIF_{50} (L/min)<100; iv) Empey's Index (FEV□/PEF)>10 mL/L/min. Table 1 summarizes the results of the study.

Discussion

UAO is a distinct clinical condition with diverse causes, presenting acutely or chronically based on the underlying etiology and type of obstruction. It is classified as variable UAO if obstruction

Table 1. Results of qualitative and quantitative criteria for upper airway obstruction.

	UAO criteria	Total positive	COPD-C	COPD-I
1	Visual FV Loop	27%		
	Insp	13 (7%)	4 (2%)	9 (5%)
	Exp	39 (20%)	18 (9%)	21 (11%)
2	FEF_{50}/FIF_{50}			
	<0.3	85 (44%)	46 (24%)	39 (20%)
	>1	33 (17%)	6 (3%)	27 (14%)
3	FIF_{50} (L/M)			
	<100 L/m	53 (27%)	14 (7%)	39 (20%)
4	Empey's Index			
	FEV1/PEF>10 mL/L/min	0	0	0
5	Aggregate criteria			
	3 out of 4 criteria	14 (7.2%)	3 (2%)	11 (6%)

UAO, upper airway obstruction; COPD-C, smoking-related chronic obstructive pulmonary disease; COPD-I, infection-related chronic obstructive pulmonary disease; FEF_{50}, forced expiratory flow at 50% of vital capacity; FIF_{50}, forced inspiratory flow at 50% of vital capacity.

OPEN ACCESS

changes with respiration or fixed if it remains constant. Variable UAO is further subtyped by location into VET UAO and VIT UAO [10]. In variable intrathoracic obstruction, airway narrowing varies with transmural pressure, causing reduced forced expiration but relatively normal inspiration. In contrast, variable extra-thoracic obstruction impairs forced inspiration, while expiration remains largely unaffected. In fixed UAOs, the airway diameter remains unchanged despite variations in transmural pressure during inspiration and expiration. As a result, both inspiratory and expiratory airflow are reduced, regardless of whether the obstruction is intrathoracic or extra-thoracic in location [11]. Patients with UAO are usually asymptomatic unless the airway is significantly narrowed. Resting dyspnea typically occurs when the airway diameter is reduced to 5 mm, while dyspnea during physical activity may appear when the diameter is around 8 mm. It is important to note that airway narrowing must be about 80% before it becomes detectable on spirometry, especially when considering factors like age, gender, and body mass index. One key difference between UAO and lower airway conditions (like obstructive or restrictive lung diseases) on spirometry is that FEV1 tends to remain nearly normal or only slightly affected in UAO [7].

Another important tool for identifying UAO is peak inspiratory flow (PIF), a simple, bedside, non-invasive, and quantitative parameter used to evaluate the severity of UAO. PIF is useful for assessing both the severity of obstruction and the response to treatment. It can also help detect severe obstruction early, potentially preventing emergency interventions such as tracheostomy. A limitation of PIF is that it is less sensitive to mild obstruction cases. PIF may appear normal until an obstruction is severe. PIF is effort-dependent [12]. We did not use PIF in our study.

Definitive diagnosis of UAO involves imaging and direct visualization *via* laryngoscopy or bronchoscopy. However, spirometry is the most widely used pulmonary function test, which assesses both the volume and speed of airflow, making it essential for diagnosing, staging, and monitoring COPD patients; thus, it is routinely done in COPD patients [10]. The FVL can be used as a screening tool for detecting the presence of UAO as well as identifying the site (intrathoracic or extra-thoracic) and the nature (fixed or variable) of the obstruction [8,13]. Therefore, both the visual appearance of the FVL envelope (Figure 1) and the calculation of UA indices should be considered during interpretation [8].

Until now, there are several studies that have demonstrated the presence of UA symptoms in COPD patients. Hurst *et al*. examined a well-defined cohort of 65 patients with COPD and found that 88% of these patients reported some degree of UA symptoms [14]. None of the studies have been conducted for UAO in COPD. The dynamic hyperinflation in COPD-C and parenchymal involvement in COPD-I have an impact on the UA and can cause UAO.

In the current study, we investigated the co-existence of the UAO component in spirometry among patients with COPD. COPD presents with significant airflow limitation, but the involvement of the UAs, which may complicate the interpretation of spirometry results, has not been extensively examined. To our knowledge, our study is the first to look at this association and the




Figure 1. Shape of normal flow volume curve and volume curve in various upper airway obstructions. PEFR, peak expiratory flow rate; FEF_{50}, forced expiratory flow at 50% of vital capacity; RV, residual volume; FIF_{50}, forced inspiratory flow at 50% of vital capacity; UAO, upper airway obstruction.

first to employ the UAO criteria in patients with COPD. Our findings highlight the distinctive features of UAO in COPD patients and underscore the importance of considering UA involvement in their diagnostic and management strategies.

This study identified UAO components in 52 patients (27%) *via* FVL analysis, with inspiratory loop flattening in 13 patients (7%) suggesting extra-thoracic obstruction, predominantly in the COPD-I group. This finding aligns with literature suggesting that recurrent infections in COPD-I can lead to UA inflammation and edema, contributing to extra-thoracic obstruction [14]. In COPD-C, minimal inspiratory flattening likely reflects emphysema-induced lung hyperinflation, which stabilizes extra-thoracic airways through tracheal traction [15]. Expiratory loop flattening (20% overall, higher in COPD-I) correlates with bronchial wall thickening and mucus plugging, consistent with infection-related small airway remodeling and expiratory airflow limitation in COPD-C, likely reflecting intrinsic small airway disease and emphysematous destruction, reducing elastic recoil [16,17]. Reduced FIF_{50} (<100 L/min) was observed in 27.3% of patients, predominantly in those with COPD-I (20.2% of patients), suggesting UA narrowing due to chronic inflammation. This finding is supported by studies demonstrating elevated levels of interleukin-6 and tumor necrosis factor-α in infection-predominant COPD [18]. $FEF_{50}/FIF_{50}>1$ was observed in 33 patients (17%) (mostly COPD-I 14%); this ratio indicates extra-thoracic obstruction, consistent with laryngeal dysfunction in recurrent infection models [19]. The FEF_{50}/FIF_{50} ratio was less than 0.3 in 85 patients (44%), with COPD-C 24% and COPD-I 20%, indicating that variable intrathoracic obstruction was the most prevalent type of UAO. The high proportion of $FEF_{50}/FIF_{50}<0.3$ (variable intrathoracic obstruction) aligns with COPD's intrinsic small airway pathology. The absence of Empey's Index (FEV1/PEF>10) in all patients could suggest low intensity of UA involvement. It can also be due to selection bias, as in the original study done by Empey, which included all cases with severe UAO with evident stridor on clinical examination [20]. Notably, only 7.21% met ≥3 diagnostic criteria for UAO (*e.g.*, FVL flattening, FIF_{50}<100 L/min), suggesting that isolated UAO markers may lack specificity in this population [21,22].

While FVL analysis is critical for detecting UAO, its interpretation in COPD requires caution. For example, distal airway obstruction in severe COPD may mimic intrathoracic UAO on spirometry, as seen in a case where a tracheal mass was initially misdiagnosed as COPD [21]. Current guidelines stress spirometry for diagnosing obstructive lung diseases, but this study highlights the need for adjunct imaging or bronchoscopy when UAO is suspected.

Conclusions

The study found that there is an UAO component in patients with COPD further limiting airflow and altering the FVL. The added resistance from UA narrowing complicates spirometry, exacerbating the obstructive pattern and worsening lung function. Further research is needed to refine our understanding of how UA involvement impacts these diseases and to guide more effective management strategies.

Limitations

The study's retrospective design, small size, and reliance on spirometry alone may under-detect structural UAO causes. Larger cohorts and longitudinal data are needed to assess UAO's impact on disease progression. Severe airflow obstruction can mask UAO on FVL, requiring advanced imaging, bronchoscopy and laryngoscopy to assess its extent and correlate it with spirometry for better clinical evaluation.

References

1. Suhas HS, Utpat K, Desai U, Joshi JM. The clinico-radiological profile of obliterative bronchiolitis in a tertiary care center. Lung India 2019;36:313-8.
2. GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet Respir Med 2020;8:585-96.
3. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis and management of COPD: 2023 report. Available from: http://goldcopd.org/2023-gold-report-2.
4. Obling N, Rangelov B, Backer V, et al. Upper airway symptoms and small airways disease in chronic obstructive pulmonary disease, COPD. Respir Med 2022;191:106710.
5. Gaga M, Vignola AM, Chanez P. Upper and lower airways: similarities and differences. Eur Respir Mon 2001;18:1-15.
6. Modrykamien AM, Gudavalli R, McCarthy K, et al. Detection of upper airway obstruction with spirometry results and the flow-volume loop: a comparison of quantitative and visual inspection criteria. Respir Care 2009;54:474-9.
7. Al-Khlaiwi T, Habib SS. Utility of spirometry in assessment of upper airway obstructions: the neglected parameters. Khyber Med Univ J 2023;15:60-5.
8. Lunn WW, Sheller JR. Flow volume loops in the evaluation of upper airway obstruction. Otolaryngol Clin North Am 1995;28:721-9.
9. Graham BL, Steenbruggen I, Miller MR, et al. Standardization of spirometry 2019 update. An official American thoracic society and European respiratory society technical statement. Am J Respir Crit Care Med 2019;200:e70-88.
10. Utpat K, Desai U, Laldayal D, et al. Role of spirometry with flow volume loop in the diagnosis of upper airway obstruction: a study from the pulmonary medicine department of a tertiary care center. Pneumon 2021;34:15.
11. Brusasco V, Pellegrino R. Pulmonary function interpretative strategies: from statistics to clinical practice. Eur Respir J 2022;60:2200317.
12. Sanchez-Guerrero J, Guerlain J, Samaha S, et al. Upper airway obstruction assessment: peak inspiratory flow and clinical COPD questionnaire. Clin Otolaryngol 2018;43:1303-11.
13. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005;26:948-68.
14. Hurst JR, Wilkinson TMA, Donaldson GC, et al. Upper airway symptoms and quality of life in chronic obstructive pulmonary disease (COPD). Respir Med 2004;98:767-70.
15. O'Donnell, D.E., Milne, et al. Dyspnea in COPD: new mechanistic insights and management implications. Adv Ther 2020;37:41-60.
16. Martinez-Garcia MA, Campos-Rodriguez F, Barbé F, et al. Precision medicine in obstructive sleep apnoea. Lancet Respir Med 2019;7:456-64.
17. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-53.

OPEN ACCESS

18. Wedzicha JA, Calverley PMA, Albert RK, et al. Prevention of COPD exacerbations: a European Respiratory Society/ American Thoracic Society guideline. Eur Respir J 2017;50:1602265.
19. Miller MR, Crapo R, Hankinson J, et al. General considerations for lung function testing. Eur Respir J 2005;26:153-61.
20. Empey DW. Assessment of upper airways obstruction. Br Med J 1972;3:503-5.
21. Amaza IP, Lee S, Sanchez R. Large endotracheal tumor presenting as severe COPD: flow-volume loop analysis, not always a straightforward diagnostic test. BMJ Case Rep 2018; 2018:bcr2018226430.
22. Santra A, Dutta P, Manjhi R, et al. Clinico-radiologic and spirometric profile of an indian population with post-tuberculosis

Received: 23 April 2025; Accepted: 22 October 2025; Early view: 27 October 2026.

Contributions: all authors have contributed significantly to this study and have approved the final manuscript.

Conflict of interest: the authors declare that there are no conflicts of interest to disclose.

Ethics approval and consent to participate: the study protocol was approved by the Ethics Committee for Academic Research Projects (ECARP)PG Academic Committee, TN. Medical College & BYL Nair Ch. (ECARP Reference No. ECARP /2O22/124).

Informed consent: written informed consent was obtained from patients to participate in the study. The manuscript does not contain any individual person's data in any form.

Patient consent for publication: not applicable.

Availability of data and materials: the datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Declaration of generative artificial intelligence and artificial intelligence-assisted technologies in the writing process: AI was not used in writing this article.

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

OPEN ACCESS